Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data At 2024 AHA Annual Meeting; New Zerlasiran Data Show Significant Time-Averaged Lp(a) Reductions With Effects Persisting 60 Weeks Following The First Dose
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data At 2024 AHA Annual Meeting; New Zerlasiran Data Show Significant Time-Averaged Lp(a) Reductions With Effects Persisting 60 Weeks Following The First Dose
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, and simultaneously published in the Journal of the American Medical Association (JAMA).New zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 weeks following the first dose
新的zerlasiran數據顯示，在首次給藥後，Lp(a)的時間平均降低顯著，效果持續60周。
Represents first study to report time-averaged Lp(a) results to further evaluate potential clinical benefits
這是第一項報告時間平均Lp(a)結果的研究，以進一步評估潛在的臨床效益。
Data simultaneously published in the Journal of the American Medical Association
數據同時發表在《美國醫療協會雜誌》中。
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, and simultaneously published in the Journal of the American Medical Association (JAMA).
Silence therapeutics plc，納斯達克：SLN（"Silence"或"公司"），是一家全球臨床階段的生物技術公司，致力於通過精確設計的藥物通過沉默疾病來改變人們的生活，今天展示了其2期ALPACAR-360研究中zerlasiran的治療結束數據，該研究針對高脂蛋白(a) [Lp(a)]水平（≥125 nmol/L）的動脈粥樣硬化心血管疾病（ASCVD）患者。這些數據在美國心臟協會（AHA）2024年科學年會的最新科學會議上於伊利諾伊州芝加哥展示，並同時發表在《美國醫療協會雜誌》（JAMA）上。
Results presented today showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks. This is the first study to report time-averaged Lp(a) analyses, which more accurately evaluates the effects of treatment over time, including intervals between doses. Maximum Lp(a) reductions exceeded 90%. At the final visit, 60 weeks following initial drug administration, reductions in Lp(a) persisted and no safety concerns emerged with infrequent dosing.
今天展示的結果表明，zerlasiran（每16周300毫克， 每24周300毫克或每24周450毫克）在36周內使Lp(a)濃度的平均時間調整減少量超過80%。這是第一項報告時間平均Lp(a)分析的研究，更準確地評估了治療在時間上的效果，包括給藥間隔。最大Lp(a)降低超過90%。在最後一次訪視中，首次用藥後60周，Lp(a)的降低持續存在，並且沒有出現任何安全隱患，給藥頻次不高。
譯文內容由第三人軟體翻譯。
